Mar 13, 2006|
Pharma: MNC or domestic?
MNC pharma stocks have been in the reckoning over the past few months aided by news of new product launches. In this write-up, we shall find out how these companies have fared in the recently concluded quarter and what are the prospects going forward. We have included the companies, Glaxo, Pfizer and Novartis for the purpose of our analysis.
MNC pharma: A comparison
|Operating profit (EBIDTA)
|EBIDTA margin (%)
|Profit before tax
|Profit after tax/(loss)
|Net profit margin (%)
|* Includes Glaxo, Pfizer and Novartis
What does the analysis say?
As can be seen from the table, the combined topline of the three companies have risen noticeably on the back of a strong performance of their pharmaceuticals business (especially the top brands). Most of these companies have also been focusing on reducing the contribution of 'drugs under price control', which have also helped matters. However, margins were under considerable pressure largely due to a spurt in raw material and staff costs. Rise in raw material costs was attributed to the increase in purchase of finished goods, which is due to higher excise duty paid on formulations purchased from third parties. Bottomline posted a decent double-digit growth largely due a considerable rise in other income and fall in depreciation charges.
The scenario back then...
In the past, MNC companies were slow in launching products due to the absence of the product patent law in the country until January 01, 2005. It must be noted that in the 1980s, both domestic and MNC companies cornered an equal slice of the Indian pharma pie. With the government giving recognition to only process patents in the country, many domestic pharma companies thrived on the back of superior 'reverse engineering skills.' This also made the MNC companies averse to launching global products in the Indian markets. Consequently the share of MNC companies reduced from 50% in 1980 to around 23% in 2004 (Source: ORG-IMS).
Back in the limelight...
Nevertheless, in recent times, MNC pharma stocks have considerably run up. The optimism is on the back of the fact that most of these companies are planning to accelerate the pace of product launches from their respective parent's portfolio or are undergoing restructuring exercises. Also, intense competition and price erosion in the global generics space has probably shifted the focus from domestic companies focusing on the exports markets to MNC companies, which have a relatively stable revenue stream. While Pfizer has already launched three products parent's folio in the last two months, Glaxo has four products lined up for the Indian market. While this a very positive step, it could take around two to three years for these new products to capture significant market share and investors need to accordingly attune their investment horizon.
What to look out for?
We remain positive on the growth prospects of MNC pharma companies due to their growing commitment in launching products, which we believe will be the most important factor in giving them an edge over their domestic peers in the Indian market. Having said that, there are certain points, which an investor cannot afford to ignore:
Strength of the parent company's pipeline: We believe that a rich product pipeline of the parent company will ensure a steady flow of new products into the domestic market as well. Therefore, the R&D pipeline of the parent assumes significant importance.
Relevance of the Indian company to the parent: A rich pipeline by itself will have no significance unless the parent company also takes an interest in the Indian subsidiary in contributing to its overall operations. A significant commitment of the parent will definitely propel the launch of products into the country.
Risk of a 100% subsidiary: If the parent company launches products, through its 100% subsidiary and not through the listed entity, investors could lose out significantly in the long term.
Nevertheless, the introduction of the patent law has been a major transition in the Indian pharma market and despite issues, is likely to signify exciting times ahead for MNC pharma majors.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 19, 2017
Ever heard of Lindy Effect? Find out how you can use it to pick timeless stocks.
Aug 18, 2017
Buying the index now will hardly help make money in stocks even in ten years.
Aug 18, 2017
Donald J Trump, a wrasslin' fan, took a 'Holy Sh*t!' blow on Tuesday.
Aug 17, 2017
PersonalFN simplifies the mutual fund account statement for you.
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407